Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma

Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morb...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 2012-07, Vol.130 (1), p.e243-e247
Main Authors: Demir, Haci Ahmet, Ekici, Filiz, Yazal Erdem, Arzu, Emir, Suna, Tunç, Bahattin
Format: Article
Language:English
Subjects:
Cardiovascular disease
Care and treatment
Diagnosis
Everolimus
Heart Neoplasms - congenital
Heart Neoplasms - diagnosis
Heart Neoplasms - drug therapy
Humans
Infant mortality
Infant, Newborn
Male
Newborn babies
Pediatrics
Protein Kinase Inhibitors - therapeutic use
Rhabdomyolysis
Rhabdomyoma - congenital
Rhabdomyoma - diagnosis
Rhabdomyoma - drug therapy
Risk factors
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment.
ISSN:0031-4005
1098-4275
DOI:10.1542/peds.2011-3476